Search hospitals > Colorado > Denver
Colorado Blood Cancer Institute
Claim this profileDenver, Colorado 80218
Global Leader in Multiple Myeloma
Global Leader in Plasma Cell Neoplasm
Conducts research for Parotid Gland Cancer
Conducts research for Lymphoma
Conducts research for Adult T-Cell Leukemia/Lymphoma
294 reported clinical trials
12 medical researchers
Summary
Colorado Blood Cancer Institute is a medical facility located in Denver, Colorado. This center is recognized for care of Multiple Myeloma, Plasma Cell Neoplasm, Parotid Gland Cancer, Lymphoma, Adult T-Cell Leukemia/Lymphoma and other specialties. Colorado Blood Cancer Institute is involved with conducting 294 clinical trials across 470 conditions. There are 12 research doctors associated with this hospital, such as Nicholas DiBella, Alireza Eghtedar, Michael Tees, MD, and Marcello Rotta.Area of expertise
1Multiple Myeloma
Global LeaderStage II
Stage I
Stage III
2Plasma Cell Neoplasm
Global LeaderStage II
Stage I
Stage III
Top PIs
Nicholas DiBellaRocky Mountain Cancer Centers-Boulder6 years of reported clinical research
Expert in Parotid Gland Cancer
Expert in Breast Cancer
103 reported clinical trials
193 drugs studied
Alireza EghtedarColorado Blood Cancer Institute3 years of reported clinical research
Studies Adult T-Cell Leukemia/Lymphoma
Studies Myeloid Leukemia
12 reported clinical trials
25 drugs studied
Michael Tees, MDColorado Blood Cancer Institute3 years of reported clinical research
Studies Lymphoma
Studies Non-Hodgkin's Lymphoma
7 reported clinical trials
10 drugs studied
Marcello RottaColorado Blood Cancer Institute1 year of reported clinical research
Studies Acute Myeloid Leukemia
Studies Adult T-Cell Leukemia/Lymphoma
7 reported clinical trials
23 drugs studied
Clinical Trials running at Colorado Blood Cancer Institute
Multiple Myeloma
Breast Cancer
Lung Cancer
Acute Myeloid Leukemia
Cancer
Plasma Cell Neoplasm
Lymphoma
Adult T-Cell Leukemia/Lymphoma
Melanoma
Cutaneous Melanoma
Teclistamab + Lenalidomide
for Multiple Myeloma
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.
Recruiting3 awards Phase 35 criteria
Ide-cel + Lenalidomide
for Multiple Myeloma
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
Recruiting2 awards Phase 31 criteria
Lenalidomide +/- Daratumumab
for Multiple Myeloma
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment. Patients are treated for up to 7 years from Step 2 reg and followed for up to 15 years.
Recruiting2 awards Phase 317 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Colorado Blood Cancer Institute?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.